The Biotech Growth Trust PLC

BIOG:LSE

The Biotech Growth Trust PLC

Actions
  • Price (GBX)1,126.00
  • Today's Change-22.00 / -1.92%
  • Shares traded53.78k
  • 1 Year change-25.73%
  • Beta0.8066
Data delayed at least 20 minutes, as of Dec 03 2021 16:35 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year The Biotech Growth Trust PLC grew revenues 241.91% from 65.96m to 225.51m while net income improved 229.11% from 60.90m to 200.43m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-4.67%
Return on equity-5.01%
Return on investment-5.01%
More ▼

Cash flow in GBPView more

Cash flow information is not available for The Biotech Growth Trust PLC.
Cash flow per share--
Price/Cash flow per share--
Book value per share13.27
Tangible book value per share13.27
More ▼

Balance sheet in GBPView more

The Biotech Growth Trust PLC uses little debt in its capital structure as supported by a debt to capital ratio of 3.37%.
Current ratio0.1218
Quick ratio--
Total debt/total equity0.0349
Total debt/total capital0.0337
More ▼

Growth rates in GBP

Year on year, growth in earnings per share excluding extraordinary items increased 271.12%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-110.00
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.